Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery

Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion in its latest funding round led by existing investor Thrive Capital.

The funding round, completed at an undisclosed valuation, also included other existing investors, Google Ventures and Alphabet, along ‌with new ⁠backers ⁠MGX, Temasek and CapitalG.

The development comes amid a broader industry push to demonstrate practical applications of AI in the healthcare sector, including its ability to accelerate research and development along with shortening drug discovery timelines.